Basal cochlear lesions result in increased amplitude of otoacoustic emissions

被引:22
作者
Kakigi, A
Hirakawa, H
Harel, N
Mount, RJ
Harrison, RV
机构
[1] Hosp Sick Children, Dept Otolaryngol, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Dept Otolaryngol, Auditory Sci Lab, Toronto, ON, Canada
关键词
aminoglycoside; amikacin; ototoxicity; otoacoustic emission; monitoring; scanning electron microscopy; cochleogram; auditory brainstem evoked responses;
D O I
10.1159/000013806
中图分类号
R36 [病理学]; R76 [耳鼻咽喉科学];
学科分类号
100104 ; 100213 ;
摘要
We have measured the changes in transient otoacoustic emissions (TEOAEs) and distortion product otoacoustic emissions (DPOAEs) during and after ototoxic amikacin treatment in an animal (chinchilla) model. TEOAE and DPOAE were recorded from 6 adult chinchillas over a 6-week time course starting just before a 5-day or 7-day treatment period with amikacin sulphate (400 mg/kg/day, i.m.). After final recordings, cochlear morphology was assessed by scanning electron microscopy. Generally, both DPOAE and TEOAE amplitudes change during and after treatment in a systematic fashion. High-frequency components change first, followed by lower-frequency components. We note that there is often a long latency to the onset of changes in otoacoustic emissions (OAE), and that these changes can continue for weeks after treatment. Most importantly we report that when the basal region of the cochlea is damaged in the frequency region above the OAE recording bandwidth (0.6-6 kHz for TEOAE; 1-6.7 kHz for DPOAE), we often find an increase in OAE amplitudes. More specifically, we note that as a cochlear lesion progresses apically, there is often a transient increase in a frequency-specific OAE before it reduces or is lost. Our results suggest that the increase in OAE amplitudes precedes the expression of detectable cochlear pathology.
引用
收藏
页码:361 / 372
页数:12
相关论文
共 27 条
[1]  
BARZA M, 1977, J MAINE MED ASSOC, V68, P194
[2]  
BRAY P, 1987, British Journal of Audiology, V21, P191, DOI 10.3109/03005368709076405
[3]   ACOUSTIC DISTORTION PRODUCTS CAN BE USED TO MONITOR THE EFFECTS OF CHRONIC GENTAMICIN TREATMENT [J].
BROWN, AM ;
MCDOWELL, B ;
FORGE, A .
HEARING RESEARCH, 1989, 42 (2-3) :143-156
[4]  
Brummett R.E., 1982, AMINOGLYCOSIDES MICR, P419
[5]  
CAMPBELL KCM, 1993, OTOLARYNG CLIN N AM, V26, P903
[6]   GENTAMICIN BLOOD-LEVELS - GUIDE TO NEPHROTOXICITY [J].
DAHLGREN, JG ;
ANDERSON, ET ;
HEWITT, WL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1975, 8 (01) :58-62
[7]   A FREQUENCY-POSITION MAP FOR THE CHINCHILLA-COCHLEA [J].
ELDREDGE, DH ;
MILLER, JD ;
BOHNE, BA .
JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA, 1981, 69 (04) :1091-1095
[8]   HIGH-FREQUENCY AUDIOMETRIC MONITORING STRATEGIES FOR EARLY DETECTION OF OTOTOXICITY [J].
FAUSTI, S ;
LARSON, VD ;
NOFFSINGER, D ;
WILSON, RH ;
PHILLIPS, DS ;
FOWLER, CG .
EAR AND HEARING, 1994, 15 (03) :232-239
[9]   COMPARISON OF THE NEPHROTOXICITY AND AUDITORY TOXICITY OF TOBRAMYCIN AND AMIKACIN [J].
GATELL, JM ;
SANMIGUEL, JG ;
ZAMORA, L ;
ARAUJO, V ;
BONET, M ;
BOHE, M ;
DEANTA, MTJ ;
FARRE, M ;
ELENA, M ;
BALLESTA, A ;
MARIN, JL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (06) :897-901
[10]  
HARRISON RV, 1979, SCAND AUDIOL, P83